Zulassungserweiterung Für ALK-Tyrosinkinaseinhibitor Crizotinib

Im Focus Onkologie
doi 10.1007/s15015-016-2347-y
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Springer Science and Business Media LLC

Related search

Zulassungserweiterung Für Gliptin

Info Diabetologie
2012English

Zulassungserweiterung Für Grippemedikament

MMW Fortschritte der Medizin
Medicine
2010English

Gute Daten Für Neuen Tyrosinkinaseinhibitor

Info Onkologie
2016English

A Novel EML6-ALK FBXO11-ALK Double Fusion Variant in Lung Adenocarcinoma and Response to Crizotinib

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

Outcomes of ALK Positive Lung Cancer Patients Treated With Crizotinib or Second-Generation ALK Inhibitor: A Monoinstitutional Experience

Oncotarget
Oncology
2018English

P2.13-07 CUX1-ALK: A Novel ALK Rearrangement That Responds to Crizotinib in Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-positive Advanced NSCLC Patient

Molecular and Clinical Oncology
Cancer ResearchOncology
2018English

Diffuse Hemorrhagic Brain Metastases in an ALK Fusion Positive Patient on Crizotinib

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy